The Itch of Liver Disease

Seminars in Cutaneous Medicine and Surgery

Volumn 30, Issue 2, 2011, Pages 93-98

  Bergasa, Nora V ^a,b  

^a METROPOLITAN HOSPITAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOTAXIN; BILE ACID; COLESTYRAMINE; GABAPENTIN; METENKEPHALIN; NALMEFENE; NALOXONE; NALTREXONE; NEUROTRANSMITTER; RIFAMPICIN; SEROTONIN; SERTRALINE; SUBSTANCE P;

CHOLESTASIS; ENZYME ACTIVITY; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLACEBO EFFECT; PRIMARY BILIARY CIRRHOSIS; PROTEIN BLOOD LEVEL; PRURITUS; REVIEW;

CHOLESTASIS; HUMANS; LIVER DISEASES; PRURITUS;

EID: 79960426034     PISSN: 10855629     EISSN: 15580768     Source Type: Journal    
DOI: 10.1016/j.sder.2011.04.009     Document Type: Review

References (53)

1. Reichen J., Simon F. Cholestasis. The Liver: Biology and Pathobiology 1988, 1105-1124. Raven, New York. J.W. Arias-Im (Ed.).
2. Bergasa N.V. Update on the treatment of the pruritus of cholestasis. Clin Liver Dis 2008, 12:219-234. x.
3. Chia S.C., Bergasa N.V., Kleiner D.E., et al. Pruritus as a presenting symptom of chronic hepatitis C. Dig Dis Sci 1998, 43:2177-2183.
4. Rishe E., Azarm A., Bergasa N.V. Itch in primary biliary cirrhosis: A patients' perspective. Acta Derm Venereol 2008, 88:34-37.
5. Lloyd-Thomas H.G., Sherlock S. Testosterone therapy for the pruritus of obstructive jaundice. Br Med J 1952, 2:1289-1291.
6. Bergasa N.V. Pruritus in primary biliary cirrhosis: Pathogenesis and therapy. Clin Liver Dis 2008, 12:385-406.
7. Thornton J.R., Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ 1988, 297:1501-1504.
8. Bergasa N.V., Alling D.W., Talbot T.L., et al. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study. J Am Acad Dermatol 1999, 41:431-434.
9. Bergasa N.V., Schmitt J.M., Talbot T.L., et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998, 27:679-684.
10. Bergasa N.V., Alling D.W., Vergalla J., et al. Cholestasis in the male rat is associated with naloxone-reversible antinociception. J Hepatol 1994, 20:85-90.
11. Bergasa N.V., Rothman R.B., Vergalla J., et al. Central mu-opioid receptors are down-regulated in a rat model of cholestasis. J Hepatol 1992, 15:220-224.
12. Inan S., Cowan A. Reduced kappa-opioid activity in a rat model of cholestasis. Eur J Pharmacol 2005, 518:182-186.
13. Ballantyne J.C., Loach A.B., Carr D.B. The incidence of pruritus after epidural morphine. J Anesth 1989, 44:863.
14. Abbound T.K., Lee K., Zhu J., et al. Prophylactic oral naltrexone with intrathecal morphine for cesarean section: Effects on adverse reactions and analgesia. Anesth Analg 1990, 71:367-370.
15. Ko M.C., Song M.S., Edwards T., et al. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004, 310:169-176.
16. Jones E.A., Bergasa N.V. The pruritus of cholestasis: From bile acids to opiate agonists. Hepatology 1990, 11:884-887.
17. Floreani A., Carderi I., Variola A., et al. A novel multidrug-resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. Hepatology 2006, 43:1152-1154.
18. Ko M.C., Naughton N.N. An experimental itch model in monkeys: Characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology 2000, 92:795-805.
19. Wei L.X., Floreani A., Variola A., et al. A study of the mu opioid receptor gene polymorphism A118G in patients with primary biliary cirrhosis with and without pruritus. Acta Derm Venereol 2008, 88:323-326.
20. Bergasa N.V., Talbot T.L., Alling D.W., et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992, 102:544-549.
21. Bergasa N.V., Alling D.W., Talbot T.L., et al. Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med 1995, 123:161-167.
22. Wolfhagen F.H., Sternieri E., Hop W.C., et al. Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study. Gastroenterology 1997, 113:1264-1269.
23. Joshi G.G., Thakur B.S., Sircar S., et al. Role of intravenous naloxone in severe pruritus of acute cholestasis. Indian J Gastroenterol 2009, 28:180-182.
24. Bergasa N.V., Liau S., Homel P., et al. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver 2002, 22:107-113.
25. Bergasa N.V., Sabol S.L., Young W.S., et al. Cholestasis is associated with preproenkephalin mRNA expression in the adult rat liver. Am J Physiol 1995, 268:G346-G354.
26. Bergasa N.V., Vergalla J., Swain M.G., et al. Hepatic concentrations of proenkephalin-derived opioids are increased in a rat model of cholestasis. Liver 1996, 16:298-302.
27. Spivey J., Jorgensen R., Gores G., et al. Methionine-enkephalin concentrations correlate with stage of disease but not pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 1994, 89:2018-2032.
28. Dietrich C.G., Geier A., Oude Elferink R.P. ABC of oral bioavailability: Transporters as gatekeepers in the gut. Gut 2003, 52:1788-1795.
29. Dombrowski S.M., Desai S.Y., Marroni M., et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001, 42:1501-1506.
30. Ikoma A., Fartasch M., Heyer G., et al. Painful stimuli evoke itch in patients with chronic pruritus: Central sensitization for itch. Neurology 2004, 62:212-217.
31. Barnes L.B., Devous M.D., Harris T.S., et al. The central nervous system activity profile of cholestatic pruritus. Hepatology 2009, 50:375A. abstract: 153.
32. O'Donohue J.W., Haigh C., Williams R. Ondansetron in the treatment of the pruritus of cholestasis: A randomised controlled trial. Gastroenterology 1997, 112:A1349.
33. Jones E.A., Molenaar H.A., Oosting J. Ondansetron and pruritus in chronic liver disease: A controlled study. Hepato Gastroenterol 2007, 54:1196-1199.
34. Mayo M.J., Handem I., Saldana S., et al. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007, 45:666-674.
35. Trivedi M., Bergasa N.V. Serum concentrations of substance P in cholestasis. Ann Hepatol 2010, 9:177-180.
36. Kremer A.E., Martens J.J., Kulik W., et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology 2010, 139:1008-1018.
37. Schoenfield L., Sjovall J., Perman E. Bile acids on the skin of patients with pruritc hepatobiliary disease. Nature 1967, 213:93-94.
38. Fiorucci S., Clerici C., Antonelli E., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 2005, 313:604-612.
39. Mencarelli A., Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med 2010, 14:79-92.
40. Bergasa N.V., McGee M., Ginsburg I.H., et al. Gabapentin in patients with the pruritus of cholestasis: A double-blind, randomized, placebo-controlled trial. Hepatology 2006, 44:1317-1323.
41. Lindor K.D., Gershwin M.E., Poupon R., et al. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
42. Parés A., Herrera M., Avilés J., et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers. J Hepatol 2010, 53:307-312.
43. Cerio R., Murphy G.M., Sladen G.E., et al. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol 1987, 116:265-267.
44. Maggiore G., Grifeo S., DeGiacomo C., et al. Phototherapy for pruritus in chronic cholestasis of childhood. Europ J Pediat 1982, 139:90-91.
45. Hanid M.A., Levi A.J. Phototherapy for pruritus in primary biliary cirrhosis. Lancet 1980, 2:530.
46. Golombek D.A., Rosenstein R.E. Physiology of circadian entrainment. Physiol Rev 2010, 90:1063-1102.
47. Bergasa N.V., Link M.J., Keogh M., et al. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease. Am J Gastroenterol 2001, 96:1563-1570.
48. Villamil A.G., Bandi J.C., Galdame O.A., et al. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med 2005, 118:1160-1163.
49. Shim W.S., Tak M.H., Lee M.H., et al. TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase. J Neurosci 2007, 27:2331-2337.
50. Kim S., Kang C., Shin C.Y., et al. TRPV1 recapitulates native capsaicin receptor in sensory neurons in association with Fas-associated factor 1. J Neurosci 2006, 26:2403-2412.
51. Binshtok A.M., Gerner P., Oh S.B., et al. Coapplication of lidocaine and the permanently charged sodium channel blocker QX-314 produces a long-lasting nociceptive blockade in rodents. Anesthesiology 2009, 111:127-137.
52. Datta D.V., Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology 1996, 50:323-332.
53. Ghent C.N., Carruthers S.G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1998, 94:488-493.